Propanc Biopharma (PPCB) News Today → Warren Buffett's 'mystery stock' (From Stansberry Research) (Ad) Free PPCB Stock Alerts $0.0007 0.00 (0.00%) (As of 05:34 PM ET) Add Compare Share Share HeadlinesStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative April 16, 2024 | finance.yahoo.comPropanc Biopharma Receives Certificate of Grant for "Composition of Proenzymes for Cancer Treatment" Patent from European Patent OfficeApril 10, 2024 | stockhouse.comPropanc Biopharma's CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic FinancingApril 8, 2024 | finance.yahoo.comPropanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic FinancingFebruary 22, 2024 | finance.yahoo.comPropanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use StudyJanuary 16, 2024 | finance.yahoo.comPropanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property OfficeDecember 18, 2023 | finance.yahoo.comPropanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment OpportunitiesDecember 13, 2023 | finance.yahoo.comPropanc Biopharma’s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRPDecember 12, 2023 | finance.yahoo.comJames Nathanielsz, CEO of Propanc Biopharma, Inc., is Featured in an Interview With SmallCapsDailyNovember 7, 2023 | finanznachrichten.dePropanc Biopharma, Inc.: Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor CellsNovember 7, 2023 | finance.yahoo.comPropanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor CellsAugust 15, 2023 | finance.yahoo.comPropanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, AustraliaJuly 26, 2023 | finance.yahoo.comPropanc Biopharma’s Clinical Candidate PRP Targeting Pancreatic Cancer Market Forecast to Reach $6.93 Billion by 2030July 13, 2023 | finance.yahoo.comPropanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 ReadsJuly 5, 2023 | finance.yahoo.comPropanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid TumorsJune 30, 2023 | sg.finance.yahoo.comPPCB - Propanc Biopharma, Inc.June 28, 2023 | finance.yahoo.comPROPANC BIOPHARMA INC (PPCB) stock forecast and price targetMay 25, 2023 | finance.yahoo.comPropanc Biopharma’s Intellectual Property Portfolio Makes Important Advancements in EuropeMay 23, 2023 | finance.yahoo.comPropanc Biopharma’s Intellectual Property Portfolio Achieves Significant Milestones in North AmericaMay 23, 2023 | finance.yahoo.comPropanc Biopharma Announces Reverse Stock SplitMarch 28, 2023 | finance.yahoo.comPropanc Biopharma Announces That PRP Suppresses TGF-β Pathway & Tumor Microenvironment in Pancreatic CancerMarch 16, 2023 | finance.yahoo.comPropanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor CellsMarch 14, 2023 | benzinga.comXeris Biopharma Holdings Stock (NASDAQ:XERS), Analyst Ratings, Price Targets, PredictionsFebruary 23, 2023 | seekingalpha.comPPCB Propanc Biopharma, Inc.January 11, 2023 | finance.yahoo.comPropanc Biopharma’s Joint Researcher Presents at the 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC)December 17, 2022 | finanznachrichten.dePropanc Biopharma, Inc.: Propanc Biopharma's Joint Researcher Receives Award at Doctoral Conference at the University of JaénDecember 15, 2022 | finance.yahoo.comPropanc Biopharma’s Joint Researcher Receives Award at Doctoral Conference at the University of JaénNovember 30, 2022 | finance.yahoo.comPropanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic CancerNovember 15, 2022 | finance.yahoo.comPropanc Biopharma’s CSO Predicts PRP Could Enhance Therapeutic Effects of Immune Checkpoint Therapy for Pancreatic CancerOctober 26, 2022 | finance.yahoo.comPropanc Biopharma’s CEO to Present at Sidoti & Company Micro-Cap Virtual Investor ConferenceOctober 12, 2022 | finance.yahoo.comPropanc Biopharma’s CEO to Attend 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC), Dec 15 - 17September 29, 2022 | finance.yahoo.comPropanc Biopharma Targets Pancreatic & Ovarian Cancers for PRP Clinical Studies with Combined Markets to Reach Over $14.3 Billion by 2027September 8, 2022 | finance.yahoo.comPropanc Biopharma Reports Significant Effects of PRP Against the Tumor MicroenvironmentAugust 23, 2022 | finance.yahoo.comPropanc Biopharma Synthesizes Recombinant Trypsinogen & Chymotrypsinogen Via POP1 Joint Research & Drug Discovery ProgramAugust 17, 2022 | finanznachrichten.dePropanc Biopharma, Inc.: Propanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Patent OfficeAugust 16, 2022 | finance.yahoo.comPropanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Patent OfficeAugust 3, 2022 | finanznachrichten.dePropanc Biopharma, Inc.: Propanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Jaén and GranadaAugust 3, 2022 | finance.yahoo.comPropanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Jaén and GranadaJuly 28, 2022 | finance.yahoo.comPropanc Biopharma’s CSO Reflects on Unique Anti-Cancer Effects of PRP Discovered Over Past DecadeJuly 19, 2022 | finance.yahoo.comPropanc Biopharma Successfully Produces Synthetic Recombinant Trypsinogen Via POP1 Joint Research & Drug Discovery ProgramJuly 13, 2022 | stockhouse.comPropanc Biopharma's CEO Believes Lead Asset Could Unlock Value as PRP Advances to Phase I, First-In-Human Study in Advanced Cancer PatientsJuly 13, 2022 | thestreet.comPropanc Biopharma Inc NewsJuly 6, 2022 | morningstar.comPropanc Biopharma’s CEO Comments on the 39 Granted Patents and 26 Patent Applications Under Examination in Key Global Jurisdictions | MorningstarJuly 6, 2022 | stockhouse.comPropanc Biopharma's CEO Comments on the 39 Granted Patents and 26 Patent Applications Under Examination in Key Global JurisdictionsJuly 5, 2022 | finance.yahoo.comPropanc Biopharma’s CEO Comments on the 39 Granted Patents and 26 Patent Applications Under Examination in Key Global JurisdictionsJune 24, 2022 | finance.yahoo.comPropanc Biopharma Announces No Immediate Plans for Reverse Stock SplitJune 22, 2022 | finance.yahoo.comPropanc Biopharma’s CSO Hails Dostarlimab’s Impressive Results Whilst Acknowledging More Work to Be Done in the Fight Against CancerJune 16, 2022 | stockhouse.comPropanc Biopharma's PRP to Target 80 - 90% of Cancer CasesJune 14, 2022 | finance.yahoo.comPropanc Biopharma’s PRP to Target 80 – 90% of Cancer CasesJune 1, 2022 | finance.yahoo.comPropanc Biopharma Believes PRP Reduced Toxicity Will Impact Cancer Patient Lives SignificantlyMay 26, 2022 | finance.yahoo.comPropanc Biopharma Presents 100 Years of Clinical Evidence for "Novel" Enzyme Therapeutic Approach to Treat Cancer Get Propanc Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for PPCB and its competitors with MarketBeat's FREE daily newsletter. Email Address Must-See: Elon’s New Invention is Absolutely Insane (Ad)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone. Click here for the full story… PPCB Media Mentions By Week PPCB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PPCB News Sentiment▼1.380.42▲Average Medical News Sentiment PPCB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PPCB Articles This Week▼20▲PPCB Articles Average Week Get Propanc Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for PPCB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Statera Biopharma News Advanced BioMedical Technologies News Boomer News Bruush Oral Care News Humanigen News Invitae News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:PPCB) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe #1 Crypto for AIWeiss RatingsWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlaceDigitizing the $11T commodities sector with one tiny stockResource Stock Digest Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Propanc Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
